Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.44 |
| ▸ | POLB | P06746 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 3/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3080134 | 1.00 | MEN1 (0.48) | MEN1KMT2ALMNATP53CXCR3 | |
| SCHEMBL3077691 | 0.88 | KMT2A (0.61) | MEN1KMT2ALMNATP53MAPT | |
| SCHEMBL3067347 | 0.86 | CCR1 (0.54) | MEN1KMT2ALMNATP53CXCR3 | |
| SCHEMBL3062839 | 0.86 | CCR1 (0.54) | MEN1KMT2ALMNATP53CXCR3 | |
| SCHEMBL12765552 | 0.78 | CCR1 (0.47) | LMNAMAPTCCR1 | |
| SCHEMBL1639548 | 0.78 | CCR1 (0.47) | MEN1KMT2ALMNAMAPTCCR1 | |
| SCHEMBL1639550 | 0.78 | CCR1 (0.47) | MEN1KMT2ALMNAMAPTCCR1 | |
| SCHEMBL14724209 | 0.76 | CCR1 (0.45) | LMNAMAPTCCR1 | |
| SCHEMBL13869125 | 0.74 | CCR1 (0.49) | CXCR3POLBRAB9ACCR1KCNH2 | |
| SCHEMBL4811812 | 0.74 | CXCR3 (0.50) | LMNACXCR3MAPTCCR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790726-B2 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CCR1, CCR3, CCR4 | MEN1 3626/4885KMT2A 4350/4885LMNA 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.